Literature DB >> 10678315

Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia.

R W Buchanan1, W T Carpenter.   

Abstract

The manifest clinical heterogeneity of schizophrenia, combined with the failure, to date, to demonstrate the existence of a unitary disease process, has led to the conceptualization of schizophrenia as a pathophysiologically heterogeneous disorder. Various approaches have been developed to define homogeneous subgroups of schizophrenic patients. An alternative approach to the use of multiple criteria for defining putative disease entities is the use of specific sign and symptom complexes, or domains of psychopathology, for reducing heterogeneity. There is now considerable evidence supporting the separation of schizophrenic symptoms into three domains: hallucinations and delusions, thought disorder, and deficit symptoms. The conceptual evolution and validating evidence for this approach are reviewed, and an illustration of how the domains of psychopathology are applied in schizophrenia research is presented.

Entities:  

Mesh:

Year:  1994        PMID: 10678315

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  42 in total

Review 1.  Gene expression profiling with DNA microarrays: advancing our understanding of psychiatric disorders.

Authors:  Julie Pongrac; Frank A Middleton; David A Lewis; Pat Levitt; Károly Mirnics
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

2.  The brief negative symptom scale: psychometric properties.

Authors:  Brian Kirkpatrick; Gregory P Strauss; Linh Nguyen; Bernard A Fischer; David G Daniel; Angel Cienfuegos; Stephen R Marder
Journal:  Schizophr Bull       Date:  2010-06-17       Impact factor: 9.306

3.  Symptom dimensions and outcome in schizophrenia.

Authors:  Raimo K R Salokangas
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

Review 4.  Persistent negative symptoms in schizophrenia: an overview.

Authors:  Robert W Buchanan
Journal:  Schizophr Bull       Date:  2006-11-10       Impact factor: 9.306

5.  Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study

Authors:  Deanna L. Kelly; Haley K. Demyanovich; Katrina M. Rodriguez; Daniela Ciháková; Monica V. Talor; Robert P. McMahon; Charles M. Richardson; Gopal Vyas; Heather A. Adams; Sharon M. August; Alessio Fasano; Nicola G. Cascella; Stephanie M. Feldman; Fang Liu; MacKenzie A. Sayer; Megan M. Powell; Heidi J. Wehring; Robert W. Buchanan; James M. Gold; William T. Carpenter; William W. Eaton
Journal:  J Psychiatry Neurosci       Date:  2019-07-01       Impact factor: 6.186

6.  Disentangling Disease Heterogeneity with Max-Margin Multiple Hyperplane Classifier.

Authors:  Erdem Varol; Aristeidis Sotiras; Christos Davatzikos
Journal:  Med Image Comput Comput Assist Interv       Date:  2015-11-18

7.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

8.  RDoC and DSM-5: what's the fuss?

Authors:  William T Carpenter
Journal:  Schizophr Bull       Date:  2013-07-24       Impact factor: 9.306

9.  Current psychopathological issues in psychosis: towards a phenome-wide scanning approach.

Authors:  Manuel J Cuesta; Victor Peralta
Journal:  Schizophr Bull       Date:  2008-05-14       Impact factor: 9.306

Review 10.  The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question.

Authors:  Vina M Goghari; Scott R Sponheim; Angus W MacDonald
Journal:  Neurosci Biobehav Rev       Date:  2009-09-20       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.